Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study

References

• De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, Van De Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–303.
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27.
   PubMed Web of Science ®Google Scholar
• Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg. 2009;13:1–5.
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009;23:15–21.
   PubMed Web of Science ®Google Scholar
• De BD. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28:39–43.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009;13:S102–S106.
   PubMed Web of Science ®Google Scholar
• Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20:60–67.
   PubMed Web of Science ®Google Scholar
• Fabroni C, Gori A, Troiano M, Prignano F, Lotti T. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2010;25(5):549–553.
   Google Scholar
• Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology 2009;219:353–356.
   PubMed Web of Science ®Google Scholar
• Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23:896–904.
   PubMed Web of Science ®Google Scholar
• Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010;146:1315–1316.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology. 2010;221:172–178.
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58:224–231.
   PubMed Web of Science ®Google Scholar
• Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernandez M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2010;25(5):579–586.
   Google Scholar
• Marchesoni A, Altomare G, Matucci-Cerinic M, Balato N, Olivieri I, Salvarani C, An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. J Eur Acad Dermatol Venereol. 2010;24:578–586.
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206–212.
   PubMed Web of Science ®Google Scholar
• Aktan S, Ilknur T, Akin C, Ozkan S. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2007;32:141–144.
   PubMed Web of Science ®Google Scholar
• Kacar N, Ergin S, Erdogan BS. The comparison of nail psoriasis severity index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol. 2008;22:219–222.
   PubMedGoogle Scholar
• Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs. 2009;69:1141–1152.
   PubMed Web of Science ®Google Scholar
• Barrera MV, Habicheyn S, Mendiola MV, Herrera CE. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008;18:683–687.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P, Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69:394–399.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159:453–456.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–592.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar